The following cannabis—induced disorders are described in other chapters of the manual with disorders with which they share phenomenology (see the substance/medication-induced mental disorders in these chapters): cannabis-induced psychotic disorder ("Schizophrenia
Disorders”); and cannabis-induced sleep disorder (”Sleep-Wake Disorders"). For cannabis intoxication delirium, see the criteria and discussion of delirium in the chapter ”Neurocog- nitive Disorders.” These cannabis-induced disorders are diagnosed instead of cannabis in- toxication or cannabis withdrawal when the symptoms are sufficiently severe to warrant independent clinical attention.
292.9 (F12.99)
This category applies to presentations in which symptoms characteristic of a cannabis- related disorder that cause clinically significant distress or impairment in social, occupa- tional, or other important areas of functioning predominate but do not meet the full criteria for any specific cannabis-related disorder or any of the disorders in the substance-related and addictive disorders diagnostic class.
A. A pattern of phencyclidine (or a pharmacologically similar substance) use leading to clinically significant impairment or distress, as manifested by at least two of the follow- ing, occurring within a 12-month period: 1.
2.
10.
Phencyclidine is often taken in larger amounts or over a longer period than was in- tended.
There is a persistent desire or unsuccessful efforts to cut down or control phency— clidine use.
A great deal of time is spent in activities necessary to obtain phencyclidine, use the phencyclidine, or recover from its effects.
Craving, or a strong desire or urge to use phencyclidine.
Recurrent phencyclidine use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences from work or poor work performance related to phencyclidine use: phencyclidine-related absences, suspensions, or ex- pulsions from school; neglect of children or household).
personal problems caused or exacerbated by the effects of the phencyclidine (e.g..
arguments with a spouse about consequences of intoxication; physical fights).
Important social, occupational, or recreational activities are given up or reduced be- cause of phencyclidine use.
Recurrent phencyclidine use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by a phencyclidine).
Phencyclidine use is continued despite knowledge of having a persistent or recur- rent physical or psychological problem that is likely to have been caused or exac- erbated by the phencyclidine.
Tolerance, as defined by either of the following: a. A need for markedly increased amounts of the phencyclidine to achieve intoxi- cation or desired effect.
b. A markedly diminished effect with continued use of the same amount of the phencyclidine.
Note: Withdrawal symptoms and signs are not established for phencyclidines, and so this criterion does not apply. (Withdrawal from phencyclidines has been reported in animals but not documented in human users.)
Specify if:
In early remission: After full criteria for phencyclidine use disorder were previously met, none of the criteria for phencyclidine use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the phencyclidine," may be met).
In sustained remission: After full criteria for phencyclidine use disorder were previ- ously met, none of the criteria for phencyclidine use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the phencyclidine," may be met).
Specify if:
In a controlled environment: This additional specifier is used if the individual is in an environment where access to phencyclidines is restricted.